E-Book 2nd Congress

  • The Effect of Beneficial Bacteriophage as a Supplement along with Antibiotics
  • Ali Ahmadi,1,* Ali Neshaee Moghadam,2
    1. M.Sc. Student, Department of Genetics, Faculty of Advanced Technologies and Science in Medicine, Islamic Azad University Tehran Medical Science, Tehran, Iran
    2. M.Sc. Student, Department of Genetics, Faculty of Agriculture and Basic Science, Islamic Azad University Qaemshahr Branch, Qaemshahr, Iran


  • Introduction: Bacterial resistance can be considered as one of the most serious threats facing the earth's inhabitants, so that according to the 4.95 million deaths associated with bacterial resistance, lower respiratory tract infections alone account for approximately 33 percent of all deaths. A person who had contracted Klebsiella pneumoniae infection and showed resistance to antibiotics was saved by combination therapy of phage and antibiotics and the phage used in it showed no side effects for the patient. Another person was also used to treat drug-resistant Pseudomonas aeruginosa spinal cord infection, which was treated well and side effects were not reported and only the person suffered from diarrhea, in addition, in treatment with bacteriophage for prosthetic joint infection, the use of bacteriophage can be considered as an alternative treatment for limited surgery. Currently, antibiotics are recommended for most bacterial diseases, but because antibiotics harm beneficial bacteria in addition to the desired bacteria, it is also recommended to use phage therapy, which is contaminated due to the specificity of the only bacteria and does not enter into the beneficial bacteria of the patient's body. The use of bacteriophages is low cost and requires less time than antibiotic production. The aim of this study was to determine the beneficial use of bacteriophage as a supplement along with antibiotics.
  • Methods: This interventional research method was conducted with narrative review approach in 2022 by searching for keywords such as Bacteriophage, Pseudomonas aeruginosa, Antibiotics, Respiratory System infection in valid databases such as Scopus, PubMed, Direct Science and Web of Science. Finally, 15 articles were studied, of which 10 were included in the study.
  • Results: Based on studies from other researchers' papers, the results of this study are that phage therapy is an emerging option for complex BJI and especially in the worldwide age of resistance dissemination. Currently no phage is commercially available, and some companies have recently conducted clinical trials regulating burn patients or in patients with bacteremia, with no immune signal published little data on phage therapy in BJI patients especially in patients with spinal infection due to multidrug-resistant P. aeruginosa. We believe that personalized phage therapy is a potentially complex BJI adjunct therapy, especially because of the pandrug-resistant P. aeruginosa. In fact, without antibiotics that have anti-biofilm activity (meaning rifampin in infections associated with Staphylococcal implants, or fluoroquinolones in gram-negative infections), the cumulative probability of failure in patients with implant-related infections is considered very high. In the case presented here, fluoroquinolone could not be used due to the multidrug resistance profile of the strain, and the potential anti-biofilm activity of phages used to treat the patient is likely to help with treatment. And it can also be very important for future treatments of such severe bacterial infections. In fact, as demonstrated here, Europe's unique academic collaboration in the field of life-saving treatment will facilitate the provision of important data that creates and conducts clinical trials at the most important relevant indication.
  • Conclusion: In the present case, a time limiting agent of screen, production, and purification of bacteriophages (total of 3 months) before a pre-assembled, personalized and targeted phage can be prescribed to the patient as a contributor to surgery and antibiotics. As a result, access to a set of refined phages can be used in a short delay.
  • Keywords: Bacteriophage, Pseudomonas aeruginosa, Antibiotics, Respiratory System infection